Saturday, April 20, 2024

Altasciences Boosts Bioanalytical Capabilities with Expanded Laboratory Space

Similar articles

Altasciences has expanded its laboratory space to 8,000ft2, enhancing its ability to meet the increasing demands of sponsors. The enlarged space accommodates a test material department and features advanced equipment and 48 workbenches. It provides a variety of services, such as flow cytometry, ligand binding assays, biomarker analysis, and cell culture capabilities.

According to Altasciences co-chief operating officer, Marie-Hélène Raigneau, this expansion is a significant advancement in enhancing their bioanalytical capabilities. The focus on growth aligns with Altasciences’ mission to facilitate the development of potentially life-saving therapeutics as efficiently as possible, and to accelerate their speed to market.

The company’s integrated CRO/CDMO services merge bioanalytical services with preclinical and clinical study solutions, manufacturing services, and all complementary research support services to enhance efficiency.

This is the third purpose-built laboratory for Altasciences. All three laboratories in North America are uniformly designed and managed. The company’s laboratory sciences possess the regulatory, scientific, and operational knowledge necessary for the quantitation of biomarkers and drugs from discovery to preclinical to Phase IV.

These laboratories provide data for Toxicokinetics (TK), Pharmacokinetics (PK), and Pharmacodynamics (PD) determinations, supporting both preclinical and clinical studies. The full-service solutions provided by Altasciences include preclinical safety testing, clinical pharmacology and proof of concept, program management, bioanalysis, medical writing, clinical monitoring, biostatistics, and data management.

Altasciences’ laboratory expansion not only enhances the company’s bioanalytical capabilities but also corresponds with its mission to facilitate the development and faster delivery of potentially life-saving therapeutics. This new space will provide the necessary support for both preclinical and clinical studies, fostering the efficiency of research and development in the pharmaceutical sector.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article